ARS PHARMACEUTICALS INC

Inside ARS Pharmaceuticals: zero‑cost option buys signal long‑term confidence, hinting at future upside despite current valuation risks.

RA Capital’s new 30,000‑share option on ARS Pharmaceuticals shows cautious confidence—investors see potential upside while limiting risk.

Insider buying surge: ARS Pharmaceuticals’ executives grab zero‑cost stock options, signaling confidence in a near‑term rebound.

Karas Eric’s June 2026 trades show insider confidence in ARS Pharmaceuticals—buying low, selling high, and boosting buzz for its ImmunoTAC platform.